Alzheimer's drug Simufilam fails to meet trial expectations, Cassava Sciences stock takes major hit

[Redaktion]

Expected with high hopes by all those affected by Alzheimer's and investors alike, the Phase 3 trial of Cassava Sciences' proprietary small molecule Simufilam failed to deliver the anticipated results. As a direct consequence, the company's shares dropped from around $26 to less than $4, with no comeback yet.

https://www.notebookcheck.net/Alzheimer-s-drug-Simufilam-fails-to-meet-trial-expectations-Cassava-Sciences-stock-takes-major-hit.923489.0.html